전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Toripalimab)

Paget Disease, Extramammary; Scrotum Disease · Paget Disease, Extramammary

#PagetDiseaseExtramammary#ADC#Phase2#antibody-drug-conjugate#PagetDisease+3
Trials 17Status Recruiting
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
ADCStandard DatabasestaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#HER2+BreastCancer+1
Trials 17Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
ADCLimited DatastaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, tislelizumab+disitamab-vedotin)

Neoadjuvant Immunotherapy · Neoadjuvant Immunotherapy

#NeoadjuvantImmunotherapy#ADC#Phase2#antibody-drug-conjugate#BeiGene
Trials 17Status Recruiting
AntibodyLimited DatastaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 16Status Active
CGTLimited DatastaleBeam Therapeutics Inc.Phase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Recruiting
AntibodyLimited DatastaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 16Status Recruiting
CGTLimited DatastaleDutch Cancer SocietyPhase 1

UCB-NK cells (UCB-NK cells)

Recurrent Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

#RecurrentOvarianCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Active
CGTLimited DatastalePaolo Caimi, MDPhase 1

BAFF CAR-T (BAFF CAR-T)

Relapsed CLL; Refractory CLL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 15Status Recruiting
CGTLimited DatastaleLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 15Status Recruiting
AntibodyLimited DatastaleALX Oncology Inc.Phase 2

ALX148 (Evorpacept, Evorpacept (ALX148))

Breast Cancer, Metastatic · Breast Cancer, Metastatic

#BreastCancerMetastatic#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 15Status Recruiting
AntibodyLimited DatastaleRochePhase 1

trastuzumab (Herceptin, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab)

Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#Antibody#Phase1#monoclonal-antibody#AdvancedMalignantSolidNeoplasm+1
Trials 15Status Discontinued
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

Advanced Unresectable or Metastatic Solid Malignancy · Advanced Unresectable or Metastatic Soli

#AdvancedUnresectableorMetastatic#Antibody#Phase2#monoclonal-antibody#Roche
Trials 15Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR T cells (4SCAR T cells)

Breast Cancer · Autoimmune Diseases

#AutoimmuneDiseases#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 14Status Recruiting
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
CGTLimited DatastaleShanghai Mingju Biotechnology C…Phase 1

JWCAR029 (JWCAR029)

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active
CGTLimited DatastaleNkarta, Inc.Phase 1

NKG2D CAR-NK (NKG2D CAR-NK)

Refractory Metastatic Colorectal Cancer · AML

#AML#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 14Status Active
CGTLimited DatastaleTaizhou HoudeAoke Biomedical Co…Phase 1

OH2 oncolytic virus (OH2 oncolytic virus)

Digestive System Neoplasms · Digestive System Neoplasms

#DigestiveSystemNeoplasms#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active
AntibodyLimited DatastaleBayerPhase 2

anetumab ravtansine (anetumab ravtansine)

Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#monoclonal-antibody#FallopianTubeEndometrioidAdenoca+2
Trials 14Status Discontinued

22 / 121 pages

← PreviousNext →